GIP and diabetes mellitus: By inhibiting DPP-4 enzyme activity, these agents potentiate the actions of incretin hormones, namely glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), addressing key pathophysiological aspects of diabetes [8].